梅州怀孕多久能做超导可视打胎手术梅州打瘦脸针瘦脸,梅州子宫附件炎病,梅州1个月打胎费用要多少钱,梅州妇科盆腔炎是怎么回事,梅州如何引起附件炎,梅州真菌阴道炎怎样医治,梅州盆腔炎有何危害

BEIJING, Jan. 10 (Xinhuanet) -- Conflicts among hundreds of scalpers raring to stock up on the new iPhone 4S are casting a shadow over the gadget's launch on the Chinese mainland on Friday.Over the weekend, scalpers from two groups bickered and shoved each other when standing in line to purchase iPhone 4 at Apple's Sanlitun store, said witnesses.Workers from two Apple stores in Beijing told China Daily the stores have not started online bookings for the iPhone 4S so far."More than 1,000 of us have gathered to buy all the available iPhone 4 this morning," said a scalper hawking the phone outside the Sanlitun store on Sunday."We'll come again on Friday for iPhone 4S. You'll have no hope of getting an iPhone 4 or 4S from the store, but only from us."The scalpers are asking 4,450 yuan (705 U.S. dollars) for an 8-gigabyte iPhone 4, and 5,450 yuan for a smuggled iPhone 4S. Apple sells an 8-gigabyte iPhone 4 on the mainland for 3,988 yuan.An Apple employee at the Sanlitun store who declined to give her name told China Daily on Monday that the store was aware the scalpers may be planning to besiege the iPhone 4S launch, and the store has prepared for that.Calls to the public relations office of Apple China went straight to voice mail.Police of the Sanlitun police station refused China Daily's interview request.An officer of the property management company of the Sanlitun Village shopping mall, where the store is located, said on Sunday they had not been informed about the weekend fracas outside of the Apple store.But on Monday afternoon, staff members of the company dispersed the scalpers by sealing off part of the store's entrance.Workers at the Sanlitun store and property management staff confirmed two groups of scalpers fought on Saturday afternoon and Sunday when jumping the line or stopping each other to pay to get an iPhone 4.Since October 2010, Apple has ceased direct sales of iPhone 4 at its retail outlets in Beijing and Shanghai and is only accepting online orders or reservations and schedules pick-up at stores to curb rampant scalping.But the registration system for reserve and pick-up has become "momentarily unavailable because of heavy traffic volume" in recent days, said Apple's website.A scalper in his 30s outside the Sanlitun store boasted they had "hacked" Apple's reservation page. He described himself an "unofficial salesman" of Apple.Defending the actions of scalpers that lead to consumers having to pay more, he said "it's not our fault but Apple's, because they put too few products in the mainland market."This is not the first time scalpers have targeted Apple products.Two men and two women suffered minor injuries outside the Sanlitun store during a clash between a worker and angry customers as Apple fans waited to buy iPhone 4 and the newly released iPad 2 in May 2011.According to reports, the incident started when a worker confronted an alleged scalper for jumping the line. This led to a verbal conflict in which the alleged scalper was thrown against the corner of an outside wall, causing injuries to his face and wrist

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy to E. coli derived asparaginase and pegapargase chemotherapy drugs used to treat ALL.Acute lymphoblastic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell. White blood cells help the body fight infection and are formed in the bone marrow.Erwinaze is injected directly into the muscle three times a week and works by breaking down one of the body's protein building blocks (the amino acid, asparagine) that is present in the blood, and is necessary for the growth of all cells. Leukemia cells cannot produce this protein building block. When a patient is treated with Erwinaze the leukemia cells die. Normal human cells are able to make enough asparagine for their own needs through biosynthesis and will not be affected by treatment with Erwinaze."The approval of Erwinaze underscores the FDA's commitment to the approval of drugs for conditions with limited patient populations with unmet medical needs using novel trial endpoints," said Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.Side effects associated with Erwinaze treatment include serious allergic reactions, inflammation of the pancreas, high blood levels of liver enzymes, blood clotting, bleeding, nausea, vomiting and high blood sugar.

BEIJING, Oct. 13 (Xinhuanet) -- Himalayas may be one of the most potential regions to provide solar power in future, according to a new research by Japanese scientists quoted by media reports Thursday. Deserts are usually regarded as the hotbeds for capturing solar power, but some of the loftiest and coldest regions can receive more energy from the sun than some deserts, said Takashi Oozeki and Yutaka Genchi, authors of the research published in Environmental Science and Technology. To set up solar cells on Himalayas would be challenging. Transmission losses and snowfall should be taken into consideration, said the researchers with the National Institute of Industrial Science and Technology in Japan. Still, the Himalayan region is attractive, because there are large energy demands in the countries nearby."It is near regions with large future energy demands such as China and India," they said.Other cold regions that can receive solar power include Andes of South America and Antarctica, according to the study.

WASHINGTON, Oct. 6 (Xinhua) -- The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) announced Thursday a joint, large-scale, national study of tobacco users to monitor and assess the behavioral and health impacts of new government tobacco regulations.The initiative is the first large-scale NIH/FDA collaboration on tobacco regulatory research since the U.S. Congress granted FDA the authority to regulate tobacco products in an act in 2009. Scientists at NIH's National Institute on Drug Abuse and the FDA's Center for Tobacco Products will coordinate the effort."The launch of this study signals a major milestone in addressing one of the most significant public health burdens of the 21st century," said FDA Commissioner Margaret Hamburg in a statement. "The results will strengthen FDA's ability to fulfill our mission to make tobacco-related death and disease part of America's past and will further guide us in targeting the most effective actions to decrease the huge toll of tobacco use on our nation's health."Investigators will follow more than 40,000 users of tobacco- product and those at risk for tobacco use ages 12 and older. They will examine what makes people susceptible to tobacco use; evaluate use patterns and resulting health problems; study patterns of tobacco cessation and relapse in the era of tobacco regulation; evaluate the effects of regulatory changes on risk perceptions and other tobacco-related attitudes; and assess differences in attitudes, behaviors and key health outcomes in racial-ethnic, gender, and age subgroups."We are pleased to collaborate with the FDA on this study that may provide us with a better understanding of the impact of product regulation on tobacco prevention and cessation," said NIH Director Francis Collins.While smoking rates have dropped significantly since their peak in the 1960s, nearly 70 million Americans ages 12 and older were current users of tobacco products in 2010. As a result, death and disease caused by tobacco use is still a tremendous public health burden. Tobacco use is the leading preventable cause of disease, disability, and death in the United States. Cigarette smoking results in more than 443,000 premature deaths in the United States each year -- more than alcohol, illegal drug use, homicide, suicide, car accidents, and AIDS combined.

CHANGCHUN, Nov. 13 (Xinhua) -- An infrared camera set up by the World Wildlife Fund (WWF) and forestry authorities in northeast China's Jilin province has captured images of a wild Siberian tiger in the Wanda Mountains.Zhu Jiang, head of the WWF Northeast China Program Office, said Saturday that the photos, taken earlier this month, are the first images of a wild Siberian tiger taken in the mountainous area.He said the evidence consolidates the mountains' role as an important habitat for the endangered species, and reinforces the need for local authorities to tighten protection measures, especially clearing animal traps and improving animal rescue efforts.The agency estimates that there are fewer than 20 wild Siberian tigers remaining in China. They live in mountains in the northeastern Heilongjiang and Jilin provinces.Zhu said animal traps still pose a major threat to the safety of wild Siberian tigers and their prey.A wild Siberian tiger was found dead with a trap around its neck in the city of Mishan, Heilongjiang, in October.A WWF survey found an average of 1.6 traps for every 10 km of distance covered in the Siberian tiger nature reserves in Heilongjiang and Jilin last winter."The WWF hopes to cooperate with local governments to protect Siberian tigers and restore their habitats," Zhu told Xinhua. "We aim to help double the population of wild Siberian tigers in China by 2022, the next Year of the Tiger," he said.